Evotec AG has entered into a discovery and development collaboration with the Johnson & Johnson Innovation Center in CA to identify new targets for Alzheimer’s disease. Evotec will work with Janssen Pharmaceuticals, a J&J subsidiary, to discover and develop novel treatments for AD.   Janssen will fund target discovery research through research payments and progress-related milestones for the next three years and will have the opportunity to internalize selected targets and therapeu...